Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said a U.S. FDA inspection of its API manufacturing facility in Telangana concluded with one procedural observation, according to a Tuesday exchange filing.
The inspection of Unit-2 of wholly owned subsidiary Apitoria Pharma was conducted from Sept. 7 to Sept. 15, the company said.